Thomas Kramps

USPTO Granted Patents = 25 (Patent Applications = 16)

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 23)

Average Co-Inventor Count = 4.4

ph-index = 12

Forward Citations = 501(Granted Patents)

Location History:

Tuebingen, DE (2017)
Tübingen, DE (2015 - 2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12390520 - Vaccination in newborns and infants (2025-08-19),

2. 12337031 - Combination vaccine (2025-06-24),

3. 12240873 - Respiratory syncytial virus (RSV) vaccine (2025-03-04),

4. 12139513 - Respiratory syncytial virus (RSV) vaccine (2024-11-12),

5. 12083190 - Rabies vaccine (2024-09-10),

6. 12036277 - Vaccination with mRNA-coded antigens (2024-07-16),

7. 11975064 - Vaccination with mRNA-coded antigens (2024-05-07),

8. 11965000 - Respiratory syncytial virus (RSV) vaccine (2024-04-23),

9. 11931406 - Flavivirus vaccine (2024-03-19),

10. 11739125 - Respiratory syncytial virus (RSV) vaccine (2023-08-29),

11. 11690910 - Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen (2023-07-04),

12. 11672856 - Vaccination in newborns and infants (2023-06-13),

13. 11369694 - Rabies vaccine (2022-06-28),

14. 11266735 - Combination vaccine (2022-03-08),

15. 11034729 - Respiratory syncytial virus (RSV) vaccine (2021-06-15),

Title: Thomas Kramps: Innovating Respiratory Syncytial Virus Vaccines

Introduction

Thomas Kramps, located in Tübingen, Germany, is a prominent inventor known for his significant contributions to medical technology. With a remarkable portfolio of 23 patents, Kramps is at the forefront of innovations aimed at combating viral infections, particularly those caused by the Respiratory Syncytial Virus (RSV).

Latest Patents

Among his latest patents, Kramps has developed an mRNA sequence that encodes at least one antigenic peptide or protein necessary for combating RSV infections. This innovation encompasses a composition comprising multiple mRNA sequences, which is intended for the preparation of a pharmaceutical composition, especially a vaccine. Furthermore, the invention includes the utilization of this mRNA sequence or the composition for the treatment or prevention of RSV infections, showcasing therapeutic potential in this crucial area of public health.

Career Highlights

Thomas Kramps has worked with notable organizations such as CureVac AG and CureVac SE. His work in these companies has contributed to developing transformative solutions in the realm of vaccine technology, specifically in the creation of effective responses to viral infections.

Collaborations

Throughout his career, Kramps has collaborated with esteemed colleagues, including Margit Schnee and Benjamin Petsch. These partnerships have facilitated the sharing of expertise and ideas, ultimately enhancing the innovation process within the field of vaccine development.

Conclusion

In conclusion, Thomas Kramps is a distinguished inventor whose work is paving the way for new vaccines against RSV. His innovative approach and commitment to addressing viral infections will undoubtedly have a lasting impact on public health and the field of immunology.

This text is generated by artificial intelligence and may not be accurate.